Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial.
Wedemeyer H, Schöneweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T, Sagalova O, Chulanov V, Osipenko M, Morozov V, Geyvandova N, Sleptsova S, Bakulin IG, Khaertynova I, Rusanova M, Pathil A, Merle U, Bremer B, Allweiss L, Lempp FA, Port K, Haag M, Schwab M, Zur Wiesch JS, Cornberg M, Haefeli WE, Dandri M, Alexandrov A, Urban S. Wedemeyer H, et al. Among authors: chulanov v. Lancet Infect Dis. 2023 Jan;23(1):117-129. doi: 10.1016/S1473-3099(22)00318-8. Epub 2022 Sep 13. Lancet Infect Dis. 2023. PMID: 36113537 Clinical Trial.
[Experience of anticipatory therapy with IL-6 receptor inhibitors and perspectives for its use in the evolution of COVID-19].
Chulanov VP, Bakirov BA, Vezikova NN, Gorodin VN, Zhuravleva MV, Zagrebneva AI, Ivanov IG, Lomakin NV, Lukina GV, Moysova DL, Mutovina ZI. Chulanov VP, et al. Ter Arkh. 2022 Oct 12;94(8):1028-1035. doi: 10.26442/00403660.2022.08.201788. Ter Arkh. 2022. PMID: 36286985 Russian.
The Advisory Board chaired by the chief specialist in infectious diseases of the Ministry of Health of Russian Federation, Professor V.P. Chulanov was held on June 18, 2022 in Saint Petersburg. Aim. The main purpose of the Board was following discussion: the analysi …
The Advisory Board chaired by the chief specialist in infectious diseases of the Ministry of Health of Russian Federation, Professor V …
Prevalence of HBV genotypes in Central and Eastern Europe.
Deterding K, Constantinescu I, Nedelcu FD, Gervain J, Nemecek V, Srtunecky O, Vince A, Grgurevic I, Bielawski KP, Zalewska M, Bock T, Ambrozaitis A, Stanczak J, Takács M, Chulanov V, Slusarczyk J, Drazd'áková M, Wiegand J, Cornberg M, Manns MP, Wedemeyer H. Deterding K, et al. Among authors: chulanov v. J Med Virol. 2008 Oct;80(10):1707-11. doi: 10.1002/jmv.21294. J Med Virol. 2008. PMID: 18712830
Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden.
Isakov V, Chulanov V, Abdurakhmanov D, Burnevich E, Nurmukhametova E, Kozhevnikova G, Gankina N, Zhuravel S, Romanova S, Hyland RH, Lu S, Svarovskaia ES, McNally J, Brainard DM, Ivashkin V, Morozov V, Bakulin I, Lagging M, Zhdanov K, Weiland O. Isakov V, et al. Among authors: chulanov v. Infect Dis (Lond). 2019 Feb;51(2):131-139. doi: 10.1080/23744235.2018.1535186. Epub 2018 Nov 30. Infect Dis (Lond). 2019. PMID: 30499360 Clinical Trial.
[Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study].
Lebedkina MS, Fomina DS, Mutovina ZY, Mаrkina UA, Bogomolov PO, Chulanov VP, Lysenko MA, Alexeeva EI. Lebedkina MS, et al. Among authors: chulanov vp. Ter Arkh. 2023 Aug 17;95(6):494-499. doi: 10.26442/00403660.2023.06.202297. Ter Arkh. 2023. PMID: 38158969 Russian.
97 results